Adding the anti-GM-CSF* receptor-α monoclonal antibody mavrilimumab to standard care (SC) improved clinical outcomes in patients with severe coronavirus disease 2019 (COVID-19) pneumonia and systemic hyperinflammation who were not under mechanical ventilation (MV), an Italian study has shown.
Patients with acute intermittent porphyria (AIP) – the most common subtype of acute hepatic porphyria (AHP) – had significantly reduced attack rates, as well as improvements in other parameters, with givosiran, the phase III ENVISION trial has shown.
Amidst the global race for a vaccine against COVID-19, the Ad5*-vectored COVID-19 (Ad5-nCoV) vaccine gets a boost with the release of encouraging data from the phase II trial, which provide further evidence supporting the safety and immunogenicity of this vaccine.
Type of pre-operative skin preparation solution – alcohol-based chlorhexidine or alcohol- or water-based povidone iodine – had no bearing on the risk of surgical site infection (SSI) in women undergoing gynaecological laparoscopy, according to a study conducted in Australia.
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Patients who recovered from COVID-19 harbour SARS-CoV-2-specific T cells as shown in a Singapore study. This, the scientists suggest, bodes well for the development of long-term protective immunity against the coronavirus.
Proposals for a shift system and longer operating hours at Malaysian public health clinics (Klinik Kesihatan, KK) are meant to ease burdens on healthcare workers (HCWs) and improve social distancing SOPs, according to the MOH.
In the treatment of patients with heart failure with reduced ejection fraction (HFrEF), a comprehensive disease-modifying strategy combining four drugs—namely angiotensin receptor–neprilysin inhibitor (ARNI), β blocker, mineralocorticoid receptor antagonist (MRA), and sodium/glucose cotransporter 2 (SGLT2) inhibitor—yields incremental benefits that contribute to stopping or delaying clinical progression and extending survival, as shown in a study.
A higher proportion of patients with systemic lupus erythematosus (SLE) experienced improvements in joint and skin symptoms with baricitinib 4 mg once daily vs placebo in a phase II randomized, double-blind, global study.